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Abstract
Altered expression of α-synuclein is linked to Parkinson’s disease (PD). A major challenge to 
explore how the increased α-synuclein affect neurotoxicity is the lack of a suitable human 
neuronal cell model that mimics this scenario. Its expression in neural precursors affects their 
differentiation process, in addition to the neuronal adaptability and variability in maintaining a 
constant level of expression across passages. Here, we describe an SH-SY5Y line harboring Tet-
ON SNCA cDNA cassette that allows for induction of controlled α-synuclein expression after 
neuronal differentiation, which can be an important tool for PD research.
Keywords
α-synuclein; dopaminergic neurons; inducible α-synuclein expressing neuronal model for PD; 
Parkinson’s disease
INTRODUCTION
Parkinson’s disease (PD), the most common neurodegenerative disorder affecting 
movement, is characterized by the aggregation/misfolding of α-synuclein in dopaminergic 
1The pCW-FLAG-(inducible)-α-Syn plasmid is being made available in Addgene and the pCW-iFLAG-α-Syn SH-SY5Y cell line is 
available upon direct request to MLH.
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neurons. α-synuclein fibrillary inclusions in Lewy bodies and Lewy neurites are the 
hallmark feature of PD and other synucleinopathies (reviewed in [1, 2]). In familial PD, in 
addition to various SNCA gene mutations [3–5], increased α-synuclein protein levels due to 
duplication or triplication of the SNCA gene [6, 7] has been directly linked to disease 
progression and severity. Subsequent studies in rodent models that overex-press wildtype or 
mutant α-synuclein provide strong in vivo evidence linking α-synuclein overexpression and 
PD-like phenotype as well as typical α-synuclein pathology [8, 9]. Similarly, intracerebral 
administration of preformed α-synuclein fibrils in rodents induces PD-like pathology and 
movement defects [10–13]. While these cumulative in vivo evidence directly links induction 
of α-synuclein expression to PD pathology, reliable modeling of this linkage in cultured 
human mature neurons has been challenging.
The majority of in situ studies utilize transient or constitutive (stable) overexpression of α-
synuclein in neuroblastoma cells followed by their differentiation into dopamine neurons, 
and recent studies have highlighted the impact of overexpressed α-synuclein on neuronal 
differentiation [14–17]. In addition, controlling the level of ectopic expression to avoid non-
physiologically high levels of expression has been a challenge. Furthermore, induced 
pluripotent cells (iPSC) derived from autosomal dominant PD patients with SNCA 
triplication (SNCA-tri), although showing high α-synuclein levels, their differentiation to 
neurons is affected by constitutively activated α-synuclein [14, 18]. The study tested prior 
knockdown of α-synuclein in SNCA-tri iPSC cells followed by neuronal differentiation; 
however, this approach also has limitations of knockdown efficiency, reproducibility as well 
as timing/controlling α-synuclein expression post differentiation.
Here, we generated and characterized a doxycycline (Dox)-inducible α-synuclein SH-SY5Y 
cell line, which not only evaded the adverse effects of high α-synuclein levels on 
differentiation but allowed for controlled, conditional, and reproducible overexpression of α-
synuclein before/after neuronal differentiation. We propose that such an inducible neural cell 
line presents a reliable and more relevant cellular model for PD and other PD-like 
synucleinopathies, compared to other routinely used cell models.
MATERIALS AND METHODS
Construction of inducible mammalian FLAG-α-Syn expression vector
An inducible mammalian FLAG-α-Syn expression vector was generated by cloning blunt-
ended full-length α-Syn amplified from pcDNA-WT-α Syn plasmid using Deep Vent DNA 
polymerase (M0258, NEB) into a pCW-Cas9 vector (gift from Eric Lander and David 
Sabatini, Addgene plasmid 50661) [19] and digested with restriction enzymes NheI (R0131, 
NEB) and BamHI (R0136, NEB) followed by treatment with DNA polymerase I, large 
(Klenow; M0210, NEB) to generate blunt DNA ends. The primers used to amplify C-
terminal FLAG-tagged α-Syn were as follows: forward primer, 5′-ATG GAT GTA TTC 
ATG AAA GGA CT-3′; reverse primer, 5’–CAC TGT CGA CTT ACT TAT CGT CAT CGT 
CTT TGT AAT CGG CTT CAG GTT CGT AGT CTT GAT ACC-3′.
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Culture and neuronal differentiation of the SH-SY5Y line
The human neuroblastoma SH-SY5Y line was routinely maintained in regular Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS; 
Gibco) and 1% penicillin/streptomycin (Corning). Cells were cultured in Neurobasal 
medium (Gibco) supplemented with B-27, 1X Glutamax (Gibco), and 1% penicillin/
streptomycin (Corning) containing 10 μM retinoic acid (RA) for seven days to induce 
neuronal differentiation.
Generation of stably transfected SH-SY5Y line with inducible α-synuclein vector and 
induction of α-synuclein expression
Transfection of SH-SY5Y cells with pCW-FLAG-(inducible)-α-Syn plasmids was carried 
out using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. 
Dox-inducible α-Syn-expressing cells were selected against the antibiotic puromycin 
(InvivoGen) with a dose of 10 μg/mL. Dox (3 μg/mL for 0, 24, 48, or 72 h)-inducible (i) 
FLAG-α-Syn levels were optimized for 3–7-fold overexpression.
Cell viability assay
SHSY-5Y cells (4.0 × 106 cells/well) were plated in 96- well plates, and either treated with 
Dox at different time points or differentiated with RA for seven days followed by Dox 
treatment. Cell viability was evaluated at specific time points using the CCK-8 kit (CCK- 8; 
CK04–500, Dojindo Laboratories; Kumamoto, Japan) according to the manufacturer’s 
instructions.
Immunofluorescence microscopy
Cells grown in an 8-well chamber slide were fixed with 4% PFA, permeabilized with 0.2% 
Triton 100X in 1X PBS and blocked with 5% BSA-PBS-T (1× PBS with 0.1% Tween-20), 
before incubation with primary and secondary antibodies. Oligomer A11 polyclonal 
antibody (Thermo Scientific, Cat# AHB0052), and α-synuclein antibody LB 509 (Santa 
Cruz, Cat#sc-58480), ChAT antibody (Cat# AB144P, Millipore) and MAP2 antibody (Cat# 
GTX11267, Gene Tex) were used. After incubation with Alexa Fluor 488 (green) - and 558 
(red)-conjugated secondary antibodies, coverslips were mounted in DAPI (Sigma). Images 
were taken using an Olympus BX61-Regular Upright BF & Fluorescent/Reflect Microscope 
using a 60 × objective. Images were analyzed with Image-J ROI Manager using the free 
hand selection tool. The corrected total cell fluorescence (CTCF) formula was used to obtain 
the final fluorescence values: CTCF = Integrated Density – (Area of selected cell X Mean 
fluorescence of background readings).
Real time-PCR analysis for mRNA quantitation
Total RNA was isolated using RNeasy Mini Kit (Qiagen #74104). Two microgram of RNA 
were used for cDNA synthesis in a 20 μL reaction using SuperScript III reverse transcriptase 
kit (Invitrogen, #18080–044). α-synuclein expression in the samples was analyzed by SYBR 
GREEN-based Real Time PCR (7000 Real-Time PCR System; Applied Biosystems) using 
SYBR Premix Ex Taq (TaKaRa) and primers for targeted mRNA HaSynTfw 5′-AGG 
GTGTTC TCT ATG TAG G-3′ and HaSynTrv 5′-ACT GTC TTC TGG GCT ACT GC-3′ 
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[20]. HPRT expression (internal control) primer sequences used were as follows: forward 
primer, HPRT-F 5′-TGA CCTTGA TTT ATT TTG CAT ACC-3′ reverse primer, HPRT-R 
5′-CGA GCA AGA CGT TCA GTC CT-3′. Data were presented as fold change mRNA 
expression with respect to the reference samples set at 1 based on 2–ΔΔCT method.
Immunoblotting of cell extracts
Preparation of whole cell extracts and protein quantitation was performed as previously 
described [21]. Following electrophoresis separation in a 4–16% gradient gel, proteins were 
transferred onto a PVDF membrane fixed with 0.4% paraformaldehyde (PFA) in 1X PBS for 
30 min at room temperature (RT), and blocked with 5% skim milk in 1X TBS-T. The 
membranes were incubated with primary antibody diluted in 1% skim milk in TBS-T for 1 h 
at RT or overnight at 4°C, followed by washing in 1 × TBS-T and then incubation with 
secondary antibody for 1 h at RT and development with SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Fisher).
Statistical analysis
Graphpad prism 6 software was used for data analysis. Comparisons of groups were 
generated with two-way ANOVA followed by Sidak’s or Tukey’s multiple comparison test 
to compare selected pair of means. p-values are indicated in the associated figure legends.
RESULTS AND DISCUSSION
Transient or constitutive expression of α-synuclein in cultured neural precursor cells and 
differentiated neurons have been modeled previously to study the biological implications of 
a high level of α-synuclein expression in neurons. These studies utilized conventional 
approaches to transfect α-synuclein expression vectors into neural precursor cells or 
differentiated neurons, using conventional transfection approaches. However, there are 
inherent limitations and challenges to this approach. First, expression of α-synuclein in 
neural precursor cells prior to differentiation significantly affects differentiation efficiency 
[14]. Moreover, such constitutive expression leads to strong cellular adaptability and a 
progressive decrease in sensitivity to PD-linked etiological factors, contrary to the 
progressive increase in neuronal dysfunction that is observed in PD. As shown in 
Supplementary Figure 1A–C, a constitutively overexpressing SH-SY5Y line failed to 
maintain similar levels of α-synuclein across passages and over time showed loss of 
overexpression. This was likely due to the mortality of cell population with higher levels of 
α-synuclein and survival/propagation of cells with moderate/reduced α-synuclein 
expression. Critically, cellular adaptability to a persistently increased amount of α-synuclein 
maybe a contributing factor to the loss of toxic effects. Likewise, transfection of 
differentiated neurons using viral vectors or electroporation is limited by variable efficiency 
as well as cell toxicity and thus its routine utilization is a challenge [22].
To overcome these limitations, we generated an inducible cell line by stably transfecting SH-
SY5Y cells with an α-synuclein cDNA cassette containing a CMV promoter under the 
control of Tet-on response element (Fig. 1A and Supplementary Figure 1D). The vector also 
possesses a distal Tet-repressor sequence, which prevented any leaky expression of α-
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synuclein in uninduced cells. The stable clone selection using puromycin ensured survival of 
cells harboring the ectopic α-synuclein cassette. Treatment of pCW-iFLAG-α-Syn SH-
SY5Y cells with 3 μg/mL Dox induced an ~3, 7, and 6-fold increase in FLAG α-synuclein 
at 24, 48, and 72 h, post induction, respectively (Fig. 1B). We then differentiated the pCW-
iFLAG-α-Syn SH-SY5Y cells using retinoic acid [23, 24] for 7 days before inducing with 
Dox, which again yielded a similar expression pattern (Supplementary Figure 1E). This is 
consistent with α-synuclein mRNA levels at the same time points (Supplementary Figure 
1F). The presence of a Tetrepressor element likely ensures a tight and highly reproducible 
pattern of protein induction. Notably, comparison of α-synuclein mRNA levels upon Dox-
induction, before and after neuronal differentiation revealed that the increase in mRNA 
levels correlated with α-synuclein protein levels in differentiated neurons, but not in 
undifferentiated cells. This suggests a cross-talk between α-synuclein levels and neuronal 
differentiation that coincides with the critical role of α-synuclein in neurons.
Formation of α-synuclein aggregates and inclusion bodies is a key feature of α-synuclein 
overexpression-mediated neurotoxicity [25, 26]. We observed a progressive increase in α-
synuclein oligomers after α-synuclein induction as analyzed by microscopy using an 
oligomer-specific antibody A11 (Fig. 1C, D). Cell viability was moderately higher in 
differentiated cells compared to undifferentiated cells overexpressing α-synuclein 
(Supplementary Figure 1G), possibly due to the replication stress activated upon 
accumulation of DNA strand breaks induced by the presence of α-synuclein in the 
chromatin [21].
We next compared the differentiation efficiency before and after α-synuclein induction. 
Immunofluorescence microscopy of cells for markers of differentiated neurons microtubule-
associated protein 2 (MAP2) and choline acetyltransferase (ChAT), clearly showed that α-
synuclein induction significantly affected neuronal differentiation (Fig. 2A, B). α-synuclein 
induction after differentiation did not affect the MAP2 and ChAT levels. Moreover, higher 
α-synuclein levels during differentiation led to poor neuronal morphology and shorter 
neurites.
Together, these data underscore the importance of avoiding α-synuclein overexpression 
during neuronal differentiation. Efficient physiologically relevant differentiation can be 
achieved with an inducible α-synuclein expressing neural cell line as we show here. The 
pros and cons of an inducible α-synuclein cell line versus a constitutive and transient 
expression models is tabulated in Table 1. Our inducible α-synuclein cell line thus provides 
an ideal system for obtaining mechanistic insights of α-synuclein-mediated neuronal 
degeneration in PD pathogenesis.
CONCLUSIONS
Modeling of α-synuclein pathology in cellular and animal models that closely represent key 
aspects of human PD has been a fundamental challenge in understanding the molecular 
pathways involved in α-synuclein induced neurotoxicity in PD and in exploring ways to 
ameliorate these pathways. The early promise of PD patient-derived iPSC cells with (SNCA-
tri), although, consistently shows higher α-synuclein levels and many aspects of 
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neurotoxicity, the constitutively increased α-synuclein limits its faithful neuronal 
differentiation [14]. The limitations of existing models in presenting key features of human 
synucleinopathies together with limited tight-reproducibility of the underlying pathology 
poses a significant challenge for translating the in-cellulo findings to in vivo models and 
human PD. From this perspective, the Dox-inducible pCW-iFLAG-α-Syn SH-SY5Y line 
reported here, allows ectopic expression of α-synuclein in a controlled and reproducible 
fashion. An important advantage of this stable cell line is its post-differentiation induction of 
expression, thereby preventing any non-physiological protein expressions during the 
differentiation process. Although, a neuroblastoma line was reported here as a proof-of-
concept to demonstrate the advantages of an inducible α-synuclein expression system, a 
similar approach can be utilized to generate iPSC or neural progenitor cell line, which can 
be differentiated to various neuronal types before α-synuclein induction.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Generation and characterization of inducible α-synuclein (α-Syn) expressing neuronal line. 
A) Schematic representation of doxycycline-inducible pCW-iFLAG-α-Syn vector used to 
generate SHSY-5Y stable cell line and immunoblot showing time-dependent induction of 
FLAG α-synuclein. B) Densitometry analysis of FLAG and endogenous α-synuclein 
immunocontent normalized to GAPDH. C) Immunofluorescence of oligomer conformations 
upon α-synuclein expression. Anti-oligomer A11 antibody recognizes all types of 
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oligomers, but not monomers and fibrils in the case of α-synuclein. D) Oligo A11 antibody 
fluorescence intensity per cells. Measurement from 30 cells from three different fields.
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Fig. 2. 
Impact of α-synuclein expression prior to and post differentiation with retinoic acid (RA). 
A) Immunofluorescence analysis to determine α-synuclein effect on differentiation markers. 
Pre α-Syn (+) cells were first induced with Dox for 3 days and then differentiated for 7 days. 
Post α-Syn (+) cells were first differentiated for 7 days and then induced with dox for 3 
days. B) MAP2 fluorescence intensity per cells. Measurement from 40 cells from four 
different fields. ****p ≤ 0.0001.
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Table 1
Pros and Cons of inducible α-synuclein expression over transiently or constitutive α-synuclein expressing 
lines
Inducible Constitutive Transient
Not limited by transfection efficiency Not limited by transfection efficiency Limited by transfection efficiency
Controlled overexpression that is unaffected 
across cell passages
Controlled overexpression for a limited 
number of passages due to mortality of 
overexpressing cells
Short time overexpression, whose efficiency/
consistency varies from experiment to experiment
Allows for the comparison of α-Syn effect 
in the same cell lineage (i.e., treated vs. 
untreated with Dox)
A cell line with no α- Syn 
overexpression is needed as a control
Allows for the comparison of α-Syn effect in the 
same cell lineage (i.e., transfected with α-Syn 
vector vs. transfected with empty vector).
α-Syn overexpression can be induced after 
differentiation to avoid α-Syn effect on 
differentiation
Differentiation is affected by the 
presence of α-Syn
Viral transductions or electroporation are required 
for overexpressing α-Syn, which are limited by 
transfection efficiency and toxicity
Green shades indicate pros and cells in orange shade indicate cons.
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